Eli Lilly and Co. (LLY) clearly did not spend Monday afternoon scrolling aimlessly through its deal pipeline. The drugmaker announced a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. to develop targeted cancer therapies, a pact that could be worth up to $5.9 billion in milestone payments to Stipple, plus royalties on any products that make it to market.
Eli Lilly Drops Up to $5.9B on a Startup That Maps Cancer's Blind Spots
Get Lilly(Eli) & Alerts
Weekly insights + SMS alerts
What Lilly Is Actually Buying
Under the agreement, Stipple Bio gets an upfront payment and an equity investment from Lilly. The companies did not disclose the amounts, which is the standard way of saying the numbers are large enough to matter and small enough to keep quiet. Lilly secures exclusive worldwide rights to develop and commercialize products arising from the collaboration.
Stipple, for its part, will be eligible for payments tied to research, product development and commercialization milestones. It could also receive tiered royalties if Lilly successfully commercializes the therapies. That structure is the biotech equivalent of a lottery ticket with a decent base salary attached: the upfront cash keeps the lights on, and the milestones pay out only if the science cooperates.
The Science: Hitting Tumors, Not Everything Else
Here is where it gets interesting. Stipple Bio will use its proprietary Pointillist Platform to identify novel binding molecules that recognize specific sites, known as epitopes, on tumor cell surfaces. Think of it as teaching a drug to read the fine print on a cancer cell rather than just spotting the bold headline.
Lilly will then combine those discoveries with its own proprietary oncology technologies to develop cancer treatments across multiple therapeutic approaches. The goal is to improve treatment effectiveness while reducing damage to healthy tissue. That toxicity problem has historically limited the clinical use of certain cancer drug targets, which is a polite way of saying some promising drugs hit the tumor and everything else on the way there.
Stipple Bio CEO Jeff Landau said Lilly's oncology research and drug development expertise could help advance more precise cancer treatments. He added that the partnership would allow Stipple Bio to expand the therapeutic applications of its platform while continuing to develop its own pipeline. In other words, Stipple gets Lilly's muscle without giving up its own sandbox.
Stipple's Runway and What Comes Next
Stipple Bio is not arriving empty-handed. In April, the company raised $100 million in an oversubscribed Series A funding round to support early-stage clinical studies of STP-100 and expand its precision oncology pipeline using the Pointillist Platform.
The company plans to initiate a Phase 1 clinical trial in early 2027 for STP-100, its lead antibody-drug conjugate candidate for solid tumors, including pancreatic cancer. It also recently earned a spot on the 2026 Endpoints 11, an annual selection of promising privately held biotechnology companies. So this is a startup with momentum, not just a pitch deck and a dream.
Lilly's Monday Shopping Spree
The Stipple deal was not even Lilly's only move of the day. Separately, the company agreed Monday to acquire Calytrix Bio Inc. for up to $1.5 billion in cash. That agreement includes an upfront cash payment to Calytrix shareholders and additional payments tied to clinical and regulatory milestones.
Calytrix develops precision therapies for myeloproliferative neoplasms, a group of blood cancers characterized by the overproduction of blood cells. Add it all up and Lilly committed to as much as $7.4 billion in potential biotech spending in a single afternoon, which is one way to make a Monday feel productive.
LLY Price Action: Eli Lilly shares were down 1.17% at $1414.87 at the time of publication on Tuesday, according to market data. Investors, it seems, were not quite ready to hand out milestone payments of their own.
More News

Dow Drops 1.4% as Salesforce Leads Software Wreck Ahead of Anthropic's Mega IPO

NVIDIA's Jensen Huang Crisis Could Rewrite the Rules of the AI Boom

Futures Slip Ahead Of Nvidia's Big Print As Washington Watches Iran And A 5.11% Treasury Yield

Wall Street Swaps Chips for Chicken: Staples Are Crushing Tech Like It's 2001

David Tepper Dumps 46% of Alphabet and Bets $172M on Oracle's AI Debt Story

Trump Backs Lutnick in Nvidia-China Fight, Says Tough Moves Could Have Sparked a Showdown With Beijing

Elizabeth Warren Wants to Break Up CVS, UnitedHealth and Cigna: 'They Take a Cut at Every Step'

Bitcoin Near $64,000 Is an 'Attractive Entry Point,' Grayscale Says After Brutal Two Weeks
Get Lilly(Eli) & Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Dow Drops 1.4% as Salesforce Leads Software Wreck Ahead of Anthropic's Mega IPO

NVIDIA's Jensen Huang Crisis Could Rewrite the Rules of the AI Boom

Futures Slip Ahead Of Nvidia's Big Print As Washington Watches Iran And A 5.11% Treasury Yield

Wall Street Swaps Chips for Chicken: Staples Are Crushing Tech Like It's 2001

David Tepper Dumps 46% of Alphabet and Bets $172M on Oracle's AI Debt Story

Trump Backs Lutnick in Nvidia-China Fight, Says Tough Moves Could Have Sparked a Showdown With Beijing

Elizabeth Warren Wants to Break Up CVS, UnitedHealth and Cigna: 'They Take a Cut at Every Step'






